Skip to content

Individual susceptibility of different uterine contraction inhibitors to the treatment of premature birth patients

Individual susceptibility of different uterine contraction inhibitors to the treatment of premature birth patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117214
Enrollment
Unknown
Registered
2026-01-21
Start date
2026-01-25
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preterm labor

Interventions

Patients diagnosed with premature birth who were treated with Rituojun alone as Group A:NA
those who were treated with Atoxiban alone during the same period as Group B:NA
those who were treated with a combination of Rituojun and Atoxiban during the same period as Group C:NA

Sponsors

Southern Medical University Southern Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 43 Years

Inclusion criteria

Inclusion criteria: 1. Voluntary signing of the informed consent form; 2. Age >= 18; 3. Gender: Female; 4. From January 2021 to August 2024, patients treated with ritodrine alone for fetal preservation were assigned to Group A, those treated with atosiban alone as Group B, and those treated with both ritodrine and atosiban in combination as Group C at the Southern Medical University Affiliated Hospital. 5. Patients who have used ritodrine or atosiban or a combination of ritodrine and atosiban can be queried through the "Donghua Official Database" at the Southern Hospital.

Exclusion criteria

Exclusion criteria: 1. Individuals with cervical dysfunction; 2. Pregnancy >= 37 weeks (full-term); 3. Identify individuals with fetal distress or intrauterine infection; 4. Severe prenatal bleeding, especially placental abruption, placenta previa with active bleeding; 5. Individuals with preeclampsia or eclampsia; 6. Individuals with severe cardiovascular disease; 7. Those who do not control hyperthyroidism and diabetes; 8. Because surgery requires prophylactic medication for patients; 9. The patient only has medication records, but no production records, lacking complete clinical and postpartum information;

Design outcomes

Secondary

MeasureTime frame
Neonatal birth outcomes;Effective time of symptom improvement after medication;Premature birth occurs;Gestational age at delivery;Adverse reactions after medication;

Primary

MeasureTime frame
Pregnancy duration extension;

Countries

China

Contacts

Public ContactCaihua Yang

Southern Medical University Southern Hospital

xiaoyang856@163.com+86 20 6278 7235

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026